BMT Tandem "Scientific" Meeting
Ballroom I-J (Salt Palace Convention Center)
Chairs:
Nirali Shah, MD
and
Steve Grupp, MD, PhD
Summary:
Abstracts: #2460, 2325, 2482, 2557, 2257, 2112
Reduced Toxicity Conditioning with Busulfan, Fludarabine, Alemtuzumab and Allogeneic Stem Cell Transplantation From HLA-Matched Sibling Donors in Children with High Risk Sickle Cell Disease Results in Long Term Donor Chimerism and Low Incidence of Agvhd
Kavita Radhakrishnan, Yale Medical school;
Mark Geyer, AB, Massachusetts General Hospital, Harvard Medical School;
Erin Morris, RN, BSN, New York Medical College;
Lee Ann Baxter-Lowe, PhD, UCSF;
Mitchell S. Cairo, MD, New York Medical College
Post-Transplant Cyclophosphamide Is Feasible and Reduces Acute GvHD in Pediatric UCB Transplantation
Oscar Ramirez, MD MPhil, Centro Médico Imbanaco;
Viviana Lotero, MD, Fundación Valle del Lili;
Maria Ximena Castro, MD, Oncólogos Asociados de Imbanaco;
Carlos Andres Portilla, MD, Centro Médico Imbanaco;
Margarita Quintero, MD MSc, Centro Médico Imbanaco
Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Pediatric Patients with High Risk Hematologic Malignanices
Heather Jill Symons, MD, MHS, Johns Hopkins Hospital;
Allen Chen, MD, PhD, MHS, Johns Hopkins Hospital;
Christopher Gamper, MD, PhD, Johns Hopkins Hospital;
David Loeb, MD, PhD, Johns Hopkins Hospital;
Richard J. Jones, MD, The Johns Hopkins University;
Ephraim Fuchs, MD, MBA, Johns Hopkins University School of Medicine
Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease
Bita Sahaf, PhD, Stanford School of Medicine;
Sally Arai, MD, Stanford University;
Joanne Otani, RN, MSN, PHN, Stanford University;
Kelsi Schoenrock, Stanford School of Medicine;
Aaron Logan, MD, PhD, Stanford University School of Medicine;
David B. Miklos, MD, PhD, Stanford University Medical Center
Regulation of Apoptotic Pathways in Human Regulatory T Cells in Chronic Graft Versus Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Kazuyuki Murase, MD, PhD, Dana-Farber Cancer Institute;
Yutaka Kawano, MD, PhD, Dana-Farber Cancer Institute;
Jeremy Ryan, Dana-Farber Cancer Institute;
Ken-ichi Matsuoka, MD, PhD, Dana-Farber Cancer Institute;
Gregory Bascug, BS, Dana-Farber Cancer Institute;
Sean M McDonough, MS, Dana-Farber Cancer Institute;
Robert Smith, BS, Dana-Farber Cancer Institute;
Suzan Lazo-Kallanian, Dana-Farber Cancer Institute;
John Daley, PhD, Dana-Farber Cancer Institute;
John Koreth, MBBS, DPhil, Dana-Farber Cancer Institute;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Anthony Letai, MD, PhD, Dana-Farber Cancer Institute;
Jerome Ritz, MD, Dana-Farber Cancer Institute
Reactivation of Murine Cytomegalovirus Is Associated with Increased Gvhd Severity in Allogeneic Hematopoietic Cell Transplant Recipients
Senthilnathan Palaniyandi, Ph.D, University of Utah;
Sabarinath Venniyil Radhakrishnan, MD, LSUHSC-Shreveport;
Fridrik J Karlsson, Ph.D, LSUHSC-Shreveport;
Elisabeth Huber, MD, University of Regensburg Medical School;
Karen Y Stokes, Ph.D, LSUHSC-Shreveport;
Nicolai Kittan, MD, LSUHSC-Shreveport;
Gerhard C Hildebrandt, MD, LSUHSC-Shreveport
![[Visit Client Website]](images/banner.gif)